GLP1R and type 2 diabetes mellitus: On 3 January 2018, the first glucagon-like peptide-1 receptor agonist weekly formulation in China was officially approved by the State Food and Drug Administration, providing a new therapeutic option for improving glycemic control in patients with type 2 diabetes.